President Donald Trump has signed an executive order on improving Medicare.
President Donald Trump has signed an executive order on improving Medicare.
Speaking at the retirement center The Villages in Sumpter County, Florida, Trump said on Thursday that the order, titled “Protecting and Improving Medicare for Our Nation’s Seniors,” delivers on his campaign promise to defend the Medicare program.
“I made you a sacred pledge that I would strengthen, defend Medicare,” said Trump, and suggested that he was making good on his promise by signing “a very historic executive order” to ensure that Medicare “will never be taken away from you. We’re not letting anyone get close.”
The order itself claims that Democrats’ proposals to institute a “Medicare for All” system, which Trump called a “threat like never before,” would strip seniors of their choices and harm beneficiaries. “Instead of ending the current Medicare program and eliminating health choices for all Americans, my Administration will continue to protect and improve Medicare by building on those aspects of the program that work well, including the market-based approaches in the current system,” the order reads.
To achieve those goals, within 1 year, HHS will propose a regulation that will make it easier to obtain Medicare Medical Savings Accounts and include a payment model that adjusts Medicare Advantage (MA) benefits to allow beneficiaries to share in savings from the program through rebates. HHS Secretary Alex Azar will be required to outline an approach to changing Medicare fee-for-service (FFS) payments to more closely align with prices paid in MA, to propose regulation to give beneficiaries more access to providers and plans, and to propose regulations that will reduce burdens on providers and ensure appropriate reimbursement.
The order also calls for providing seniors with more information about healthcare quality and cost, eliminating waste and combatting fraud, and transitioning toward “true market-based pricing” in the FFS Medicare program, which will involve shared savings and competitive bidding.
In his remarks, Trump said that his administration is “lowering the cost of prescription drugs, taking on the pharmaceutical companies,” yet notably, the executive order did not include a provision to implement the administration’s proposed international price index (IPI) to reduce drug costs in Medicare.
In 2018, the administration released a plan to allow CMS to set prices for some drugs, including biologics and biosimilars, using prices paid in other countries as external references. While some stakeholders voiced concerns about the IPI model, the proposal did garner rare bipartisan interest, and in her own plan to lower drug prices for Medicare, House Speaker Nancy Pelosi, D-California, proposed a similar model that would cap drugs’ prices at 1.2 times the average selling price in Australia, Canada, France, Germany, Japan, and the United Kingdom. Also included in Pelosi’s plan is authorizing HHS to negotiate prices for up to 250 drugs that lack genereic or biosimilar competition.
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Cordavis Report Outlines Strategies for Biosimilar Development, Access in the US Health Care Market
May 8th 2024Cordavis, a CVS Healthspire company, released a report detailing the current hurdles faced in developing and commercializing biosimilars in the US and highlighting efforts by the organization to enhance access and affordability for these products.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.